

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/58, 31/12, 31/59, 31/44 // (A61K 31/59, 31:58, 31:44, 31:12)	A1	(11) International Publication Number: WO 97/25049 (43) International Publication Date: 17 July 1997 (17.07.97)
(21) International Application Number: PCT/EP97/00166 (22) International Filing Date: 10 January 1997 (10.01.97) (30) Priority Data: 9600604.4 12 January 1996 (12.01.96) GB (71) Applicant (for all designated States except US): THE BOOTS COMPANY PLC (GB/GB); 1 Thane Road West, Nottingham NG2 3AA (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): CLAYTON, Paul, Rodney (GB/GB); The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB). (74) Agent: THACKER, Michael, Anthony; The Boots Company plc, Group Patents Dept., Building D31, 1 Thane Road West, Nottingham NG2 3AA (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITION CONTAINING DIOSGENIN (57) Abstract The present invention relates to the treatment or prevention of osteoporosis by the administering to a subject in need thereof therapeutically effective amounts of diosgenin, vitamin K and vitamin D and optionally a therapeutically effective amount of vitamin B6 and/or vitamin A.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

COMPOSITION CONTAINING DIOSGENIN

The present invention relates to the prevention and treatment of osteoporosis and to compositions for use in such prevention or treatment.

Compositions for the prevention and treatment of osteoporosis according to the present invention comprise a therapeutically effective amount of diosgenin, a therapeutically effective amount of vitamin K and a therapeutically effective amount of vitamin D. Optionally the composition also contains a therapeutically effective amount of vitamin B6 and/or vitamin A.

Method of preventing or treating osteoporosis according to the present invention comprises the administration to a subject in need thereof a therapeutically effective amount of diosgenin, a therapeutically effective amount of vitamin K and a therapeutically effective amount of vitamin D. Optionally the method of the present invention also comprises the administration of a therapeutically effective amount of vitamin B6 and/or vitamin A. The diosgenin, vitamin K, vitamin D and optional vitamins B6 and A may be administered simultaneously or sequentially. For simultaneous administration the components may be combined into a single dosage form or may be formulated into several dosage forms which are intended to be taken at the same time.

Diosgenin [(25R)-spirost-5-en-3 β -ol] used in the compositions and method of the present invention may be used in a chemically pure form which may be isolated from natural sources (eg from yams), may be prepared by chemical modification of saponins obtained from natural sources or may be prepared synthetically. Alternatively, an extract obtained from a natural source which is rich in diosgenin or a precursor thereto may be used. A suitable source would be an extract of yam. The amount of diosgenin to be

administered per day is in the range 100 to 2000 mg preferably 150 to 1200 mg most preferably 300 to 1200mg. This amount may be administered in a single dose or in more than one dose which may be taken at different times throughout the day.

5 The term "Vitamin K" as used herein is intended to cover vitamin K in any of its forms (ie vitamin K1, vitamin K2, vitamin K3, vitamin K4, vitamin K5, vitamin K6 and vitamin K7) or any precursor or analogue to any of these vitamins (such as the naphthaquinones) which would give rise to vitamin K-like activity after administration. Preferred vitamin K components are
10 provided by vitamin K1 and/or vitamin K2. The amount of vitamin K to be administered per day is in the range 5 to 5000 µg, preferably 10 to 200 µg. This amount may be administered in a single dose or in more than one dose which may be taken at different times throughout the day.

15 The term "Vitamin D" as used herein is intended to cover vitamin D in any of its forms (ie vitamin D1, vitamin D2, vitamin D3 or vitamin D4) or any precursor or analogue to any of these vitamins which would give rise to vitamin D-like activity after administration. The preferred form of vitamin D is vitamin D3. The amount of vitamin D to be administered per day is in the
20 range 5 to 5000 µg preferably 10 to 100 µg. This amount may be administered in a single dose or in more than one dose which may be taken at different times throughout the day.

25 The term "Vitamin B6" as used herein is intended to cover pyridoxine hydrochloride or any other of the vitamins of the B6 complex (ie codecarboxylase, pyridoxal hydrochloride or pyridoxamine dihydrochloride) or any precursors or analogues thereof which would give rise to vitamin B6-like activity. The amount of vitamin B6 to be administered per day is in the range 1 to 1000 mg, preferably 5 to 100 mg. This amount may be

administered in a single dose or in more than one dose which may be taken at different times throughout the day.

The amount of vitamin A to be administered per day is in the range 1 to 4 mg. This amount may be administered in a single dose or in more than one dose which may be taken at different times during the day.

The pharmaceutical compositions of the present invention may be administered as oral dosage forms and may be solid dosage forms eg tablets, capsules, lozenges, chewable tablets or capsules or may be liquid dosage forms eg solutions, suspensions, dispersions or syrups. A preferred pharmaceutical composition is a soft-gel capsule in which the active ingredients are dissolved or dispersed in a liquid non-aqueous centre. Alternatively, the compositions of the present invention may be formulated so that the active materials are administered transdermally. Examples of suitable transdermal dosage forms are creams and gels containing the active materials or patches which may be adhesively attached to the skin and which contain a reservoir of the active material optionally in combination with a penetration enhancer or other suitable excipients.

These oral and transdermal dosage forms may be prepared by methods which are well-known to those skilled in the art.

The preferred soft gel capsules may be prepared by dissolving or suspending the active ingredients and any excipients or other desirable formulation aids in an oily medium which is then encapsulated in the soft gel capsule.

The efficacy of the compositions of the present invention and the effectiveness of the method of the present invention has been shown by means of clinical trials. In one such trial, post-menopausal female volunteers

received the compositions of the present invention containing diosgenin and vitamins K, D and B6 for a period of 84 days. All subjects were given the same amounts of vitamins K, D and B6 (120 µg of vitamin K1, 20 µg of vitamin D3 and 10 mg of vitamin B6) but individual subjects received daily
5 doses of diosgenin of 300 or 600 mg per day. The dose of diosgenin given to a particular subject remained constant throughout the trial period. Analysis of blood and urine samples taken at the start, midpoint and end of the trial showed that there were significant increases in the two most sensitive biochemical markers of bone formation, namely alkaline phosphatase activity
10 and osteocalcin levels.

In a second such trial, which is conducted on the double blind placebo controlled principle in which neither the subjects nor the physician are aware of whether the subject is receiving active material or placebo, the biochemical parameters of bone metabolism are measured in two groups of
15 post-menopausal women for a period of 18 months. One group receives the composition of the present invention and the other group receives placebo. Bone mass is also measured at appropriate points in the trial.

Claims

1. Compositions for the prevention and treatment of osteoporosis comprising a therapeutically effective amount of diosgenin, a therapeutically effective amount of vitamin K and a therapeutically effective amount of vitamin
5 D.
2. Compositions as claimed in claim 1 which also contain a therapeutically effective amount of vitamin B6 and/or vitamin A.
3. A method of preventing or treating osteoporosis comprising the administration to a subject in need thereof a therapeutically effective amount
10 of diosgenin, a therapeutically effective amount of vitamin K and a therapeutically effective amount of vitamin D.
4. The method according to Claim 3 which also comprises the administration of a therapeutically effective amount of vitamin B6 and/or vitamin A

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/EP 97/00166

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/58 A61K31/12 A61K31/59 A61K31/44 //(A61K31/59,
31:58,31:44,31:12)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE WPI Section Ch, Week 9342 Derwent Publications Ltd., London, GB; Class A96, AN 93-331352 XP002030480 & JP 05 238 929 A (DOW CORNING KK) , 17 September 1993 see abstract	1-4
A	BIOTECHNOL. LETT., vol. 13, no. 2, 1991, pages 125-130, XP000653430 RAVISHANKAR G.A. ET AL.: "Development of media for growth of dioscorea deltoidea cells and in vitro diosgenin production: influence of media constituents and nutrient stress" *cf.summary and discussion*	1-4

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 April 1997

Date of mailing of the international search report

23.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Stoltner, A

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/EP 97/00166

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ACTA MANIL, vol. 38, 1990, pages 15-18, XP000653645 ZAFAR R. ET AL.: "Diosgenin from the root culture of trigonella-foenum-graecum L." *cf. abstract and page 17, "results and discussion"</p> <p>-----</p>	1-4

THIS PAGE BLANK (USPTO)